Pharmstandard
VC Fund
Moscow, Russian Federation
Pharmstandard is a VC fund in Moscow focused on Health Care and Biotechnology. Pharmstandard JSC, Russia’s leading pharmaceutical company, develops and manufactures high-quality modern pharmaceutical products which meet the requirements of the healthcare system and the expectations of patients.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Pharmstandard invests in
Stages Pharmstandard invests in
Countries Pharmstandard invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $8.5M–$56M
Investment Focus
Industry
- Health Care 5 (56%)
- Biotechnology 5 (56%)
- Pharmaceutical 3 (33%)
- Medical 2 (22%)
- Genetics 2 (22%)
Stage
- Series B 3 (33%)
- Seed 1 (11%)
- Series C 1 (11%)
- Debt Financing 1 (11%)
- Private Equity 1 (11%)
Country
- United States 6 (67%)
- Canada 1 (11%)
- Russian Federation 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Elena Starikova
Acting Head of VC
|
Acting Head of VC | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| TearSolutions is a pharmaceutical company that specializes in providing medical solutions for dry eyes. The company is driven by its mission is to develop a novel replacement therapy for dry eye through phase II human clinical trials. The platform technology is centered on the remarkable tear protein and the proprietary drug 'Lacripep'.An outsourcing model will be used.The company was founded in Charlottesville, Virginia. | $6.4M / Debt Financing / Mar 21, 2019 | ||
| TearSolutions is a pharmaceutical company that specializes in providing medical solutions for dry eyes. The company is driven by its mission is to develop a novel replacement therapy for dry eye through phase II human clinical trials. The platform technology is centered on the remarkable tear protein and the proprietary drug 'Lacripep'.An outsourcing model will be used.The company was founded in Charlottesville, Virginia. | $8.5M / Series B / Dec 07, 2017 | ||
| Viriom Inc. is a development and commercial stage biotech company developing novel and affordable medicines against life threatening infections such as HIV and HBV. The company has an exclusive worldwide license to its phase 3 and commercial stage lead compounds (Elpida/elsulfavirine and VM1500A) from Hoffmann-La Roche and has developedproprietary drug candidates VM2500, VM3500 LAI formulations and combinations with cell, vaccine and antibody drugs for treatment, prophylaxis and cure of HIV. Viriom makes a breakthrough in treating, preventing and curing HIV and chronic HBV infections worldwide. | $12.5M / Convertible Note / Dec 06, 2017 | ||
| The company delivers genetic tests that help people to live healthier (predisposition tests), save lives (inherited deseases) and help in family planning (carrier screening). | $1M / Seed / Feb 17, 2017 | ||
| At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients. | $20M / Series C / Aug 18, 2016 | ||
| TransMedics provides technology and clinical service solutions, service for heart and lung transplant volume, clinical outcomes, and reduce learning curves. | $12.5M / Private Equity / Jul 12, 2016 | ||
| Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina. | $60M / Post-IPO Equity / Mar 15, 2016 | ||
| Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine is driving this transformational approach, which has the potential todrivesignificantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. | $56M / Series B / Apr 23, 2015 | ||
| enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expressionlevels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes. | $11.5M / Series B / Jan 26, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Pharmstandard invest in?
Pharmstandard invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Seed stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Pharmstandard's check size?
Pharmstandard typically joins rounds of $8.5M–$56M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pharmstandard participates in.
How do I contact Pharmstandard?
Public channels for Pharmstandard include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pharmstandard?
The team at Pharmstandard includes Elena Starikova (Acting Head of VC). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
